Oncotarget

Research Papers:

The long non-coding RNA EPB41L4A-AS2 inhibits tumor proliferation and is associated with favorable prognoses in breast cancer and other solid tumors

Shouping Xu, Peiyuan Wang, Zilong You, Hongxue Meng, Guannan Mu, Xianan Bai, Guangwen Zhang, Jinfeng Zhang and Da Pang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:20704-20717. https://doi.org/10.18632/oncotarget.8007

Metrics: PDF 2666 views  |   HTML 2482 views  |   ?  


Abstract

Shouping Xu1, Peiyuan Wang1, Zilong You1, Hongxue Meng2, Guannan Mu3, Xianan Bai1, Guangwen Zhang1, Jinfeng Zhang1, Da Pang1,4

1Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China

2Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China

3Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, China

4Heilongjiang Academy of Medical Sciences, Harbin, China

Correspondence to:

Da Pang, e-mail: [email protected]

Keywords: antisense lncRNA, EPB41L4A-AS2, prognostic value, proliferation, breast cancer

Received: November 12, 2015     Accepted: February 18, 2016     Published: March 09, 2016

ABSTRACT

EPB41L4A-AS2 is a novel long non-coding RNA of unknown function. In this study, we investigated the expression of EPB41L4A-AS2 in breast cancer tissues and evaluated its relationship with the clinicopathological features and prognosis of patients with breast cancer. This entailed conducting a meta-analysis and prognosis validation study using two cohorts from the Gene Expression Omnibus (GEO). In addition, we assessed EPB41L4A-AS2 expression and its relationship with the clinicopathological features of renal and lung cancers using the Cancer Genome Atlas cohort and a GEO dataset. We also clarified the role of EPB41L4A-AS2 expression in mediating cancer cell proliferation in breast, renal, and lung cancer cell lines transfected with an EPB41L4A-AS2 expression vector. We found that high EPB41L4A-AS2 expression is associated with favorable disease outcomes. Gene ontology enrichment analysis revealed that EPB41L4A-AS2 may be involved in processes associated with tumor biology. Finally, overexpression of EPB41L4A-AS2 inhibited tumor cell proliferation in breast, renal, and lung cancer cell lines. Our clinical and in vitro results suggest that EPB41L4A-AS2 inhibits solid tumor formation and that evaluation of this long non-coding RNA may have prognostic value in the clinical management of such malignancies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8007